Dishman Carbogen Amcis has released its audited financial results for the quarter and year ended March 31, 2026. The company reported a significant increase in revenue for both the fourth quarter and the full fiscal year, driven by strong performance across its CDMO and Marketable Molecules segments.

Q4 FY26 Performance

For the quarter ended March 31, 2026, the company recorded a net revenue of ₹8,514 mn, an increase of 18.9% compared to ₹7,163 mn in the same period of the previous year. The CDMO segment contributed ₹6,909 mn to the revenue, while Marketable Molecules contributed ₹1,605 mn. EBITDA for the quarter stood at ₹1,630 mn, with a margin of 19.1%, compared to an EBITDA of ₹1,527 mn and a margin of 21.3% in Q4 FY25.

FY26 Annual Results

For the full fiscal year FY26, net revenue grew by 8.1% to ₹29,319 mn from ₹27,115 mn in FY25. The CDMO segment revenue for the year was ₹24,413 mn, and Marketable Molecules revenue was ₹4,906 mn. The company achieved an EBITDA of ₹5,656 mn for FY26, translating to a margin of 19.3%, an improvement from the 17.3% margin recorded in the previous year.

Financial Metrics

The following table summarizes the key financial metrics for the quarter and full year:

The company noted that the increase in CDMO revenue was primarily driven by higher commercial revenue and development revenue from late Phase III molecules. The growth in the Marketable Molecules segment was attributed to increased supplies of Vitamin D analogues.

Dishman Carbogen Amcis Limited announced that its Board of Directors has approved the audited financial results for the quarter and year ended March 31, 2026. The meeting, held on May 19, 2026, also sanctioned key corporate actions including the re-appointment of statutory auditors and a revision to external commercial borrowing limits.

Financial Results and Auditor Appointment

The Board approved the Standalone and Consolidated Audited Financial Results for the fourth quarter and fiscal year 2026. The audit report, issued by M/s. T R Chadha & Co. LLP, Chartered Accountants, carries an unmodified opinion. Additionally, the Board recommended the re-appointment of M/s. T R Chadha & Co. LLP as Statutory Auditors for a second term of five consecutive years, subject to shareholder approval at the upcoming Annual General Meeting.

External Commercial Borrowings

In a strategic move to refinance existing debt, the Board approved raising External Commercial Borrowings (ECB) up to CHF 200 million from promoter group company Aamanya AG. This revises the earlier proposed limit of CHF 135 million. The loan, which is unsecured, carries an interest rate of SARON + 400 bps (currently 4% p.a.) and has a tenor of 10 years. The funds will be utilized to refinance existing rupee debt, meet working capital and capital expenditure requirements, and for other permitted purposes.

Borrowing Limits and Shareholder Approval

Consequent to the ECB approval, the Board passed a resolution to increase the borrowing limits under Section 180(1)(c) of the Companies Act, 2013 from Rs. 1,700 crores to Rs. 4,000 Crores. This increase is subject to shareholder approval. The company will seek the requisite consent for both the ECB and the increased borrowing limits through an Extra-Ordinary General Meeting (EGM), the date for which will be communicated later.

Key ECB Details